{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:13:37Z","timestamp":1793128417971,"version":"4.5.0"},"reference-count":188,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007480","name":"Universidad de Castilla-La Mancha","doi-asserted-by":"publisher","award":["2021-GRIN-31240"],"award-info":[{"award-number":["2021-GRIN-31240"]}],"id":[{"id":"10.13039\/501100007480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011698","name":"Regional Government of Castilla-La Mancha","doi-asserted-by":"publisher","award":["SBPLY\/21\/180501\/000050"],"award-info":[{"award-number":["SBPLY\/21\/180501\/000050"]}],"id":[{"id":"10.13039\/501100011698","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Gobierno de Espa\u00f1a Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["SBPLY\/21\/180501\/000050"],"award-info":[{"award-number":["SBPLY\/21\/180501\/000050"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.biopha.2025.118871","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:36:06Z","timestamp":1765474566000},"page":"118871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Nanotechnology-based approaches for head and neck cancer treatment"],"prefix":"10.1016","volume":"193","author":[{"given":"Almudena","family":"del Campo-Balguer\u00edas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corina","family":"Lorz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Oca\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iv\u00e1n","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Alonso-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1056\/NEJMra1715715","article-title":"Head and Neck Cancer","volume":"382","author":"Chow","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.biopha.2025.118871_bib2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40265-023-01835-2","article-title":"Treating Head and Neck Cancer in the Age of Immunotherapy, A 2023 Update","volume":"83","author":"Bhatia","year":"2023","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.biopha.2025.118871_bib3","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.3390\/cancers13112635","article-title":"Resection Margins in Head and Neck Cancer Surgery, An Update of Residual Disease and Field Cancerization","volume":"13","author":"Pierik","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib4","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib5","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s11033-024-09476-8","article-title":"Insights into metastatic roadmap of head and neck cancer squamous cell carcinoma based on clinical, histopathological and molecular profiles","volume":"51","author":"Mastronikolis","year":"2024","journal-title":"Mol. Biol. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2982","article-title":"The molecular biology of head and neck cancer","volume":"11","author":"Leemans","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib7","doi-asserted-by":"crossref","DOI":"10.4161\/21624011.2014.965570","article-title":"Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma","volume":"4","author":"Partlov\u00e1","year":"2015","journal-title":"Oncoimmunology"},{"issue":"7536","key":"10.1016\/j.biopha.2025.118871_bib8","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nature14129","article-title":"Comprehensive genomic characterization of head and neck squamous cell carcinomas","volume":"517","author":"Lawrence","year":"2015","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.biopha.2025.118871_bib9","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.2017.75.0141","article-title":"Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States","volume":"36","author":"Chaturvedi","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118871_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068329","article-title":"Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica","volume":"8","author":"Herrero","year":"2013","journal-title":"PLOS ONE"},{"issue":"3","key":"10.1016\/j.biopha.2025.118871_bib11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10555-017-9689-6","article-title":"Tobacco-related carcinogenesis in head and neck cancer","volume":"36","author":"Jethwa","year":"2017","journal-title":"Cancer Metastas.. Rev."},{"issue":"4","key":"10.1016\/j.biopha.2025.118871_bib12","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Collaboration. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990\u20132015, A Systematic Analysis for the Global Burden of Disease Study","volume":"3","author":"Global Burden of Disease Cancer","year":"2017","journal-title":"JAMA Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118871_bib13","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1016\/j.joms.2017.05.008","article-title":"Epidemiological Trends of Head and Neck Cancer in the United States, A SEER Population Study","volume":"75","author":"Mourad","year":"2017","journal-title":"J. Oral. Maxillofac. Surg."},{"issue":"5","key":"10.1016\/j.biopha.2025.118871_bib14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1535-6108(04)00112-6","article-title":"Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression","volume":"5","author":"Chung","year":"2004","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.biopha.2025.118871_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075056","article-title":"High incidence of HPV-associated head and neck cancers in FA deficient mice is associated with E7\u2019s induction of DNA damage through its inactivation of pocket proteins","volume":"8","author":"Park","year":"2013","journal-title":"PloS One"},{"issue":"23","key":"10.1016\/j.biopha.2025.118871_bib16","doi-asserted-by":"crossref","first-page":"9959","DOI":"10.1158\/0008-5472.CAN-10-1291","article-title":"Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPV-associated head and neck cancer","volume":"70","author":"Park","year":"2010","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2174\/138920209787581235","article-title":"Molecular Signature of HPV-Induced Carcinogenesis, pRb, p53 and Gene Expression Profiling","volume":"10","author":"Buitrago-P\u00e9rez","year":"2009","journal-title":"Curr. Genom."},{"issue":"5","key":"10.1016\/j.biopha.2025.118871_bib18","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/hed.25057","article-title":"Comprehensive review of genetic factors contributing to head and neck squamous cell carcinoma development in low-risk, nontraditional patients","volume":"40","author":"Gingerich","year":"2018","journal-title":"Head. Neck"},{"issue":"6","key":"10.1016\/j.biopha.2025.118871_bib19","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/jso.23406","article-title":"Prognostic role of epidermal growth factor receptor in head and neck cancer, a meta-analysis","volume":"108","author":"Zhu","year":"2013","journal-title":"J. Surg. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118871_bib20","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.3390\/ijms19071824","article-title":"Bosutinib Inhibits EGFR Activation in Head and Neck Cancer","volume":"19","author":"Segrelles","year":"2018","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118871_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.oraloncology.2018.02.014","article-title":"Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway","volume":"79","author":"Garc\u00eda-Escudero","year":"2018","journal-title":"Oral. Oncol."},{"key":"10.1016\/j.biopha.2025.118871_bib22","unstructured":"Cancer (IARC) TIA for R on. Global Cancer Observatory. [cited 2025 May 28]. GLOBOCAN 2022, Estimated cancer incidence, mortality and prevalence worldwide in 2022. Available from, https:\/\/gco.iarc.fr\/."},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib23","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC), An update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radio. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118871_bib24","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/CAD.0000000000000480","article-title":"Chemotherapy for localized head and neck squamous cell cancers","volume":"28","author":"Karabajakian","year":"2017","journal-title":"Anticancer Drugs"},{"issue":"42","key":"10.1016\/j.biopha.2025.118871_bib25","first-page":"1","article-title":"Current Therapy for Metastatic Head and Neck Cancer, Evidence, Opportunities, and Challenges","author":"Wise-Draper","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book Am. Soc. Clin. Oncol. Annu Meet."},{"key":"10.1016\/j.biopha.2025.118871_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103424","article-title":"Cetuximab in locally advanced head and neck squamous cell carcinoma, Biological mechanisms involved in efficacy, toxicity and resistance","volume":"164","author":"Muraro","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.biopha.2025.118871_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2019.104460","article-title":"Immunotherapy for head and neck cancer, Recent advances and future directions","volume":"99","author":"Cramer","year":"2019","journal-title":"Oral. Oncol."},{"issue":"7222","key":"10.1016\/j.biopha.2025.118871_bib28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0140-6736(62)91074-7","article-title":"Cancer Chemotherapy by Intra-Arterial Infusion, a Preliminary Report Concerning Tumours of the Head and Neck","volume":"279","author":"Espiner","year":"1962","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.biopha.2025.118871_bib29","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/1097-0142(197305)31:5<1141::AID-CNCR2820310515>3.0.CO;2-R","article-title":"Chemotherapy of cancer of the head and neck","volume":"31","author":"Bertino","year":"1973","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/1097-0142(197001)25:1<78::AID-CNCR2820250112>3.0.CO;2-4","article-title":"Treatment of advanced cancer of the head and neck","volume":"25","author":"Ansfield","year":"1970","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.biopha.2025.118871_bib31","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/lary.26629","article-title":"Systemic therapy for head and neck squamous cell carcinoma, Historical perspectives and recent breakthroughs","volume":"127","author":"Blasco","year":"2017","journal-title":"Laryngoscope"},{"issue":"4972","key":"10.1016\/j.biopha.2025.118871_bib32","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/205698a0","article-title":"Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode","volume":"205","author":"Rosenberg","year":"1965","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.biopha.2025.118871_bib33","first-page":"359","article-title":"CIS-Dichlorodiammineplatinum(II) in the treatment of epidermoid carcinoma of the head and neck","volume":"61","author":"Wittes","year":"1977","journal-title":"Cancer Treat. Rep."},{"issue":"10","key":"10.1016\/j.biopha.2025.118871_bib34","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.1986.4.10.1506","article-title":"Carboplatin (NSC-241-240), an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck","volume":"4","author":"Eisenberger","year":"1986","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118871_bib35","first-page":"471","article-title":"Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck","volume":"66","author":"Kish","year":"1982","journal-title":"Cancer Treat. Rep."},{"issue":"8","key":"10.1016\/j.biopha.2025.118871_bib36","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1992.10.8.1245","article-title":"Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck, a Southwest Oncology Group study","volume":"10","author":"Forastiere","year":"1992","journal-title":"J. Clin. Oncol."},{"issue":"22","key":"10.1016\/j.biopha.2025.118871_bib37","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa031317","article-title":"Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer","volume":"349","author":"Forastiere","year":"2003","journal-title":"N. Engl. J. Med"},{"issue":"24","key":"10.1016\/j.biopha.2025.118871_bib38","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJM199106133242402","article-title":"null null. Induction Chemotherapy plus Radiation Compared with Surgery plus Radiation in Patients with Advanced Laryngeal Cancer","volume":"324","year":"1991","journal-title":"N. Engl. J. Med"},{"issue":"17","key":"10.1016\/j.biopha.2025.118871_bib39","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa070956","article-title":"Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer","volume":"357","author":"Posner","year":"2007","journal-title":"N. Engl. J. Med"},{"issue":"17","key":"10.1016\/j.biopha.2025.118871_bib40","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer","volume":"357","author":"Vermorken","year":"2007","journal-title":"N. Engl. J. Med"},{"issue":"19","key":"10.1016\/j.biopha.2025.118871_bib41","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1056\/NEJMoa032641","article-title":"Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer","volume":"350","author":"Bernier","year":"2004","journal-title":"N. Engl. J. Med"},{"issue":"15_","key":"10.1016\/j.biopha.2025.118871_bib42","volume":"34","author":"Geoffrois","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2025.118871_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101426","article-title":"Therapeutic approaches for the treatment of head and neck squamous cell carcinoma\u2013an update on clinical trials","volume":"21","author":"Goel","year":"2022","journal-title":"Transl. Oncol."},{"issue":"S1","key":"10.1016\/j.biopha.2025.118871_bib44","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hed.25930","article-title":"Immune checkpoint inhibitors for head and neck squamous cell carcinoma, Current landscape and future directions","volume":"41","author":"Kao","year":"2019","journal-title":"Head. Neck"},{"key":"10.1016\/j.biopha.2025.118871_bib45","unstructured":"Research C for DE and. Nivolumab for SCCHN. FDA [Internet]. 2018 Mar 11 [cited 2025 Mar 27]; Available from, \u3008https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/nivolumab-scchn\u3009."},{"key":"10.1016\/j.biopha.2025.118871_bib46","unstructured":"Bristol-Myers Squibb. An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN) [Internet]. clinicaltrials.gov; 2022 Sept [cited 2025 Mar 27]. Report No., NCT02105636. Available from, \u3008https:\/\/clinicaltrials.gov\/study\/NCT02105636\u3009."},{"issue":"19","key":"10.1016\/j.biopha.2025.118871_bib47","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2025.118871_bib48","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.70.1524","article-title":"Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer, Results From a Single-Arm, Phase II Study","author":"Bauml","year":"2017","journal-title":"J. Clin. Oncol. [Internet]"},{"issue":"11","key":"10.1016\/j.biopha.2025.118871_bib49","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.biopha.2025.118871_bib50","unstructured":"Merck Sharp &; Dohme L.L.C. A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors [Internet]. clinicaltrials.gov; 2021 May [cited 2025 Mar 27]. Report No., NCT01848834. Available from, \u3008https:\/\/clinicaltrials.gov\/study\/NCT01848834\u3009."},{"key":"10.1016\/j.biopha.2025.118871_bib51","article-title":"and. FDA approves pembrolizumab for first-line treatment of head and neck squamous cell carcinoma","author":"Research C for","year":"2024","journal-title":"FDA [Internet]"},{"key":"10.1016\/j.biopha.2025.118871_bib52","unstructured":"Merck Sharp &; Dohme L.L.C. A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent\/Metastatic Head and Neck Squamous Cell Carcinoma [Internet]. clinicaltrials.gov; 2024 Sept [cited 2025 Mar 27]. Report No., NCT02358031. Available from, \u3008https:\/\/clinicaltrials.gov\/study\/NCT02358031\u3009."},{"issue":"9625","key":"10.1016\/j.biopha.2025.118871_bib53","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(08)60728-X","article-title":"Head and neck cancer","volume":"371","author":"Argiris","year":"2008","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.biopha.2025.118871_bib54","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1200\/JCO.2005.07.119","volume":"23","author":"Baselga","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.biopha.2025.118871_bib55","doi-asserted-by":"crossref","first-page":"5578","DOI":"10.1200\/JCO.2005.07.120","article-title":"Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck","volume":"23","author":"Herbst","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.biopha.2025.118871_bib56","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N. Engl. J. Med"},{"issue":"6","key":"10.1016\/j.biopha.2025.118871_bib57","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2025.118871_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113729","article-title":"PI3K\/AKT\/mTOR signaling as a molecular target in head and neck cancer","volume":"172","author":"Marquard","year":"2020","journal-title":"Biochem Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib59","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41199-018-0030-z","article-title":"Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC)","volume":"3","author":"Jung","year":"2018","journal-title":"Cancers Head. Neck"},{"issue":"14","key":"10.1016\/j.biopha.2025.118871_bib60","doi-asserted-by":"crossref","first-page":"7889","DOI":"10.3390\/ijms23147889","article-title":"Novel Systemic Treatment Modalities Including Immunotherapy and Molecular Targeted Therapy for Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma","volume":"23","author":"Ghosh","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118871_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107363","article-title":"Homodimerization of CB2 cannabinoid receptor triggered by a bivalent ligand enhances cellular signaling","volume":"208","author":"Navarro","year":"2024","journal-title":"Pharm. Res"},{"key":"10.1016\/j.biopha.2025.118871_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108846","article-title":"Application of proteolysis targeting chimeric (PROTAC) technology in protein regulation and drug development","volume":"164","author":"He","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.biopha.2025.118871_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117929","article-title":"Research progress of BRD4 in head and neck squamous cell carcinoma, Therapeutic application of novel strategies and mechanisms","volume":"113","author":"Tang","year":"2024","journal-title":"Bioorg. Med Chem."},{"issue":"12","key":"10.1016\/j.biopha.2025.118871_bib64","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1051\/medsci\/200925121046","article-title":"Les immunoconjugu\u00e9s, anticorps \u00ab\u00a0arm\u00e9s\u00a0\u00bb pour combattre le cancer","volume":"25","author":"Haeuw","year":"2009","journal-title":"M. \u00e9decine\/Sci."},{"issue":"6","key":"10.1016\/j.biopha.2025.118871_bib65","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.3390\/cancers15061845","article-title":"Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers","volume":"15","author":"Esapa","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2025.118871_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116378","article-title":"Antibody-drug conjugates for non-small cell lung cancer, Advantages and challenges in clinical translation","volume":"226","author":"Zhao","year":"2024","journal-title":"Biochem Pharm."},{"issue":"10","key":"10.1016\/j.biopha.2025.118871_bib67","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.3390\/ph17101338","article-title":"Present Scenario and Future Landscape of Payloads for ADCs, Focus on DNA-Interacting Agents","volume":"17","author":"Valsasina","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.biopha.2025.118871_bib68","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.biopha.2025.118871_bib69","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1021\/acs.molpharmaceut.8b00177","article-title":"Impact of Payload Hydrophobicity on the Stability of Antibody\u2013Drug Conjugates","volume":"15","author":"Buecheler","year":"2018","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2025.118871_bib70","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/cancers11030394","article-title":"Acquired Resistance to Antibody-Drug Conjugates","volume":"11","author":"Collins","year":"2019","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.biopha.2025.118871_bib71","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1007\/s11912-024-01582-x","article-title":"Economics of Antibody Drug Conjugates (ADCs), Innovation, Investment and Market Dynamics","volume":"26","author":"Bhushan","year":"2024","journal-title":"Curr. Oncol. Rep."},{"issue":"8","key":"10.1016\/j.biopha.2025.118871_bib72","doi-asserted-by":"crossref","DOI":"10.1200\/PO.24.00179","article-title":"Current Landscape of Antibody-Drug Conjugate Development in Head and Neck Cancer","author":"Park","year":"2024","journal-title":"JCO Precis Oncol."},{"issue":"13","key":"10.1016\/j.biopha.2025.118871_bib73","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.3390\/cancers13133126","article-title":"Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer, A Systematic Review","volume":"13","author":"Perrotti","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2025.118871_bib74","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.matpr.2021.10.048","article-title":"Current developments in nanotechnology for cancer treatment","volume":"48","author":"Chatterjee","year":"2022","journal-title":"Mater. Today Proc."},{"key":"10.1016\/j.biopha.2025.118871_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.805336","article-title":"A. Options to Improve the Action of PROTACs in Cancer, Development of Controlled Delivery Nanoparticles","volume":"9","author":"Juan","year":"2022","journal-title":"Front Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118871_bib76","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3390\/pharmaceutics15031025","article-title":"Nanotechnology in Cancer Diagnosis and Treatment","volume":"15","author":"Alrushaid","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.10.021","article-title":"Nanoparticles\u2014a historical perspective","volume":"331","author":"Kreuter","year":"2007","journal-title":"Int J. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib78","first-page":"17","article-title":"Nanoparticles--a new colloidal drug delivery system","volume":"53","author":"Marty","year":"1978","journal-title":"Pharm. Acta Helv."},{"issue":"5","key":"10.1016\/j.biopha.2025.118871_bib79","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/jps.2600590508","article-title":"Bead polymerization technique for sustained-release dosage form","volume":"59","author":"Khanna","year":"1970","journal-title":"J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2025.118871_bib80","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/jps.2600580916","article-title":"Epoxy resin beads as a pharmaceutical dosage form I, Method of preparation","volume":"58","author":"Khanna","year":"1969","journal-title":"J. Pharm. Sci."},{"issue":"14","key":"10.1016\/j.biopha.2025.118871_bib81","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.3390\/cancers13143387","article-title":"Polyester Polymeric Nanoparticles as Platforms in the Development of Novel Nanomedicines for Cancer Treatment","volume":"13","author":"Niza","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib82","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12951-022-01477-8","article-title":"Nanoparticle classification, physicochemical properties, characterization, and applications, a comprehensive review for biologists","volume":"20","author":"Joudeh","year":"2022","journal-title":"J. Nanobiotechnology"},{"issue":"4","key":"10.1016\/j.biopha.2025.118871_bib83","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1021\/acsabm.2c01000","article-title":"Multifunctional Carbon-Based Nanoparticles, Theranostic Applications in Cancer Therapy and Diagnosis","volume":"6","author":"Hosseini","year":"2023","journal-title":"ACS Appl. Bio Mater."},{"issue":"8","key":"10.1016\/j.biopha.2025.118871_bib84","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1021\/acs.accounts.0c00280","article-title":"Silica-Based Nanoparticles for Biomedical Applications, From Nanocarriers to Biomodulators","volume":"53","author":"Yang","year":"2020","journal-title":"Acc. Chem. Res"},{"issue":"9","key":"10.1016\/j.biopha.2025.118871_bib85","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/17425247.2021.1912008","article-title":"Metallic nanoparticles as drug delivery system for the treatment of cancer","volume":"18","author":"Neha Desai","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.biopha.2025.118871_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120485","article-title":"Dendrimers based cancer nanotheranostics, An overview","volume":"600","author":"Saluja","year":"2021","journal-title":"Int J. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2025.118871_bib87","article-title":"PEGylated liposomes enhance the effect of cytotoxic drug, A review","volume":"9","author":"Taher","year":"2023","journal-title":"Heliyon [Internet]"},{"issue":"5","key":"10.1016\/j.biopha.2025.118871_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09394","article-title":"Liposomes, structure, composition, types, and clinical applications","volume":"8","author":"Nsairat","year":"2022","journal-title":"Heliyon"},{"issue":"3","key":"10.1016\/j.biopha.2025.118871_bib89","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.3390\/ijms24032643","article-title":"Liposomes for tumor targeted therapy, a review","volume":"24","author":"Wang","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.biopha.2025.118871_bib90","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.3390\/pharmaceutics15122729","article-title":"Advances in NIR-Responsive Natural Macromolecular Hydrogel Assembly Drugs for Cancer Treatment","volume":"15","author":"Zhao","year":"2023","journal-title":"Pharmaceutics"},{"issue":"11","key":"10.1016\/j.biopha.2025.118871_bib91","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.3390\/catal12111386","article-title":"Classification, Synthetic, and Characterization Approaches to Nanoparticles, and Their Applications in Various Fields of Nanotechnology, A Review","volume":"12","author":"Khan","year":"2022","journal-title":"Catalysts"},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib92","article-title":"Toxicity of Nanoparticles in Biomedical Application, Nanotoxicology","volume":"2021","author":"Egbuna","year":"2021","journal-title":"J. Toxicol."},{"issue":"9","key":"10.1016\/j.biopha.2025.118871_bib93","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1007\/s00204-017-1993-y","article-title":"Toxicology of silica nanoparticles, an update","volume":"91","author":"Murugadoss","year":"2017","journal-title":"Arch. Toxicol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118871_bib94","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.nano.2014.02.011","article-title":"Liposomal encapsulation of dexamethasone modulates cytotoxicity, inflammatory cytokine response, and migratory properties of primary human macrophages","volume":"10","author":"Bartneck","year":"2014","journal-title":"Nanomed. Nanotechnol. Biol. Med"},{"issue":"7","key":"10.1016\/j.biopha.2025.118871_bib95","doi-asserted-by":"crossref","first-page":"9994","DOI":"10.1021\/acsnano.2c00128","article-title":"Where Is Nano Today and Where Is It Headed? A Review of Nanomedicine and the Dilemma of Nanotoxicology","volume":"16","author":"Domingues","year":"2022","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.biopha.2025.118871_bib96","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/wnan.1157","article-title":"Recent advances in stealth coating of nanoparticle drug delivery systems","volume":"4","author":"Amoozgar","year":"2012","journal-title":"WIREs Nanomed. Nanobiotechnology"},{"issue":"10","key":"10.1016\/j.biopha.2025.118871_bib97","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/jat.4157","article-title":"Therapeutic nanostructures and nanotoxicity","volume":"41","author":"Sarma","year":"2021","journal-title":"J. Appl. Toxicol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118871_bib98","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3390\/jpm11080771","article-title":"The Enhanced Permeability and Retention (EPR) Effect, The Significance of the Concept and Methods to Enhance Its Application","volume":"11","author":"Wu","year":"2021","journal-title":"J. Pers. Med"},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib99","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics, a review","volume":"65","author":"Maeda","year":"2000","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.biopha.2025.118871_bib100","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4155\/tde.13.8","article-title":"EPR-effect, Utilizing size-dependent Nanoparticle Delivery to Solid Tumors","volume":"4","author":"Stylianopoulos","year":"2013","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.biopha.2025.118871_bib101","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.msec.2019.01.066","article-title":"Employment of enhanced permeability and retention effect (EPR), Nanoparticle-based precision tools for targeting of therapeutic and diagnostic agent in cancer","volume":"98","author":"Kalyane","year":"2019","journal-title":"Mater. Sci. Eng. C."},{"issue":"9","key":"10.1016\/j.biopha.2025.118871_bib102","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1039\/D0CS01127D","article-title":"Understanding nanoparticle endocytosis to improve targeting strategies in nanomedicine","volume":"50","author":"Almeida","year":"2021","journal-title":"Chem. Soc. Rev."},{"issue":"2","key":"10.1016\/j.biopha.2025.118871_bib103","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1021\/acs.bioconjchem.8b00732","article-title":"The Endosomal Escape of Nanoparticles, Toward More Efficient Cellular Delivery","volume":"30","author":"Smith","year":"2019","journal-title":"Bioconjug Chem."},{"issue":"11","key":"10.1016\/j.biopha.2025.118871_bib104","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307800120","article-title":"Endosomal escape, A bottleneck for LNP-mediated therapeutics","volume":"121","author":"Chatterjee","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2025.118871_bib105","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1039\/c3tb00386h","article-title":"The role of endosome evasion bypass in the reversal of multidrug resistance by lipid\/nanoparticle assemblies","volume":"1","author":"Li","year":"2013","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.biopha.2025.118871_bib106","doi-asserted-by":"crossref","first-page":"8845","DOI":"10.2147\/IJN.S273713","article-title":"Distinct Proteins in Protein Corona of Nanoparticles Represent a Promising Venue for Endogenous Targeting \u2013 Part I, In vitro Release and Intracellular Uptake Perspective","volume":"15","author":"Sebak","year":"2020","journal-title":"Int J. Nanomed."},{"issue":"2","key":"10.1016\/j.biopha.2025.118871_bib107","first-page":"954","article-title":"Rational Design of Cancer Nanomedicine for Simultaneous Stealth Surface and Enhanced Cellular Uptake","volume":"13","author":"Jin","year":"2019","journal-title":"ACS Nano"},{"issue":"4","key":"10.1016\/j.biopha.2025.118871_bib108","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1021\/mp800049w","article-title":"Pharmacokinetics and Biodistribution of Nanoparticles","volume":"5","author":"Li","year":"2008","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.biopha.2025.118871_bib109","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.3390\/pharmaceutics15071844","article-title":"Localized Drug Delivery Systems, An Update on Treatment Options for Head and Neck Squamous Cell Carcinomas","volume":"15","author":"Hariharan","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2025.118871_bib110","article-title":"Nanomedicine in HNSCC therapy-a challenge to conventional therapy","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib111","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41392-023-01536-y","article-title":"Nanomedicine in cancer therapy","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib112","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12645-023-00180-z","article-title":"Anti-EGFR conjugated nanoparticles to deliver alpelisib as targeted therapy for head and neck cancer","volume":"14","author":"Juan","year":"2023","journal-title":"Cancer Nanotechnol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118871_bib113","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3390\/pharmaceutics12100986","article-title":"Controlled delivery of BET-PROTACs, in vitro evaluation of MZ1-loaded polymeric antibody conjugated nanoparticles in breast cancer","volume":"12","author":"Cimas","year":"2020","journal-title":"Pharmaceutics"},{"issue":"17","key":"10.1016\/j.biopha.2025.118871_bib114","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.3390\/ijms21176018","article-title":"Antibody conjugation of nanoparticles as therapeutics for breast cancer treatment","volume":"21","author":"Juan","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.biopha.2025.118871_bib115","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3390\/pharmaceutics12090802","article-title":"An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy","volume":"12","author":"Juan","year":"2020","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib116","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41392-023-01536-y","article-title":"Nanomedicine in cancer therapy","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"5","key":"10.1016\/j.biopha.2025.118871_bib117","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/j.apsb.2021.11.016","article-title":"The long-circulating effect of pegylated nanoparticles revisited via simultaneous monitoring of both the drug payloads and nanocarriers","volume":"12","author":"Fan","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib118","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40580-021-00274-7","article-title":"Impact of the conjugation of antibodies to the surfaces of polymer nanoparticles on the immune cell targeting abilities","volume":"8","author":"Lee","year":"2021","journal-title":"Nano Converg."},{"issue":"15","key":"10.1016\/j.biopha.2025.118871_bib119","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202409635","article-title":"Antibody-Nanoparticle Conjugates in Therapy, Combining the Best of Two Worlds","volume":"21","author":"Adhikari","year":"2025","journal-title":"Small"},{"issue":"3","key":"10.1016\/j.biopha.2025.118871_bib120","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1055\/s-0043-1772459","article-title":"Expression of CD44 in Head and Neck Squamous Cell Carcinoma\u2014An In-Silico Study","volume":"10","author":"Kavitha","year":"2023","journal-title":"Glob. Med Genet"},{"issue":"8","key":"10.1016\/j.biopha.2025.118871_bib121","doi-asserted-by":"crossref","first-page":"E312","DOI":"10.1002\/lary.24606","article-title":"In vivo optical imaging of folate receptor-\u03b2 in head and neck squamous cell carcinoma","volume":"124","author":"Sun","year":"2014","journal-title":"Laryngoscope"},{"issue":"7","key":"10.1016\/j.biopha.2025.118871_bib122","doi-asserted-by":"crossref","first-page":"768","DOI":"10.15537\/smj.2025.46.7.20240775","article-title":"Illuminating the role of VEGFA and EGFR in head and neck squamous cell carcinoma through the multi-omics data integration","volume":"46","author":"Alhegaili","year":"2025","journal-title":"Saudi Med J."},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib123","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s11671-025-04303-w","article-title":"Emerging trends in synthesis, characterization, and mechanism of action of antibody-drug and antibody-nanoparticle conjugates","volume":"20","author":"Dixit","year":"2025","journal-title":"Discov. Nano"},{"key":"10.1016\/j.biopha.2025.118871_bib124","unstructured":"Pysz I., Jackson P.J.M., Thurston D.E. Introduction to Antibody\u2013Drug Conjugates (ADCs). [cited 2025 Nov 17]; Available from, \u3008https:\/\/books.rsc.org\/books\/edited-volume\/725\/chapter\/444646\/Introduction-to-Antibody-Drug-Conjugates-ADCs\u3009."},{"key":"10.1016\/j.biopha.2025.118871_bib125","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jconrel.2021.12.013","article-title":"Benefits and challenges of antibody drug conjugates as novel form of chemotherapy","volume":"341","author":"Fatima","year":"2022","journal-title":"J. Control Release J. Control Release Soc."},{"key":"10.1016\/j.biopha.2025.118871_bib126","doi-asserted-by":"crossref","first-page":"912","DOI":"10.3762\/bjnano.14.75","article-title":"Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics","volume":"14","author":"Kumari","year":"2023","journal-title":"Beilstein J. Nanotechnol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118871_bib127","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.biopha.2025.118871_bib128","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1023\/A:1016201732368","article-title":"A Phase I Study of SPI-077 (Stealth\u00ae Liposomal Cisplatin) Concurrent with Radiation Therapy for Locally Advanced Head and Neck Cancer","volume":"20","author":"Rosenthal","year":"2002","journal-title":"Invest N. Drugs"},{"issue":"18_","key":"10.1016\/j.biopha.2025.118871_bib129","article-title":"First safety and response results of a randomized phase III study with liposomal platin in the treatment of advanced squamous cell carcinoma of the head and neck (SCCHN)","volume":"25","author":"Jehn","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib130","article-title":"Lipoplatin Formulation Review Article","volume":"2012","author":"Stathopoulos","year":"2012","journal-title":"J. Drug Deliv."},{"issue":"5","key":"10.1016\/j.biopha.2025.118871_bib131","doi-asserted-by":"crossref","first-page":"392","DOI":"10.5152\/iao.2022.21268","article-title":"Comparison of Cytotoxic and Ototoxic Effects of Lipoplatin and Cisplatin in Neuroblastoma In Vivo Tumor Model","volume":"18","author":"Evin Eskicio\u011flu","year":"2022","journal-title":"J. Int Adv. Otol."},{"key":"10.1016\/j.biopha.2025.118871_bib132","unstructured":"Privo Technologies. Phase 1\/2, Open-Label, Single-Arm Safety and Efficacy Dose-Finding, Systemic Exposure, and Device Technical Effects of PRV111 (Cisplatin Transmucosal System) in Subjects With Oral Squamous Cell Carcinoma [Internet]. clinicaltrials.gov; 2022 Sept [cited 2025 Mar 26]. Report No., NCT03502148. Available from, \u3008https:\/\/clinicaltrials.gov\/study\/NCT03502148\u3009."},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib133","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1038\/s41467-022-31859-3","article-title":"A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer","volume":"13","author":"Goldberg","year":"2022","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.biopha.2025.118871_bib134","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1001\/archotol.131.5.418","article-title":"An In Vivo Evaluation of Docetaxel Delivered Intratumorally in Head and Neck Squamous Cell Carcinoma","volume":"131","author":"Yoo","year":"2005","journal-title":"Arch. Otolaryngol. Neck Surg."},{"issue":"11","key":"10.1016\/j.biopha.2025.118871_bib135","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/01.mlg.0000177456.90870.94","article-title":"Docetaxel Associated Pathways in Cisplatin Resistant Head and Neck Squamous Cell Carcinoma, A Pilot Study","volume":"115","author":"Yoo","year":"2005","journal-title":"Laryngoscope"},{"key":"10.1016\/j.biopha.2025.118871_bib136","unstructured":"BIND Therapeutics. A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck [Internet]. clinicaltrials.gov; 2016 Apr [cited 2025 Mar 22]. Report No., NCT02479178. Available from, \u3008https:\/\/clinicaltrials.gov\/study\/NCT02479178\u3009."},{"key":"10.1016\/j.biopha.2025.118871_bib137","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.105173","article-title":"Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer, A single-arm, multicenter, phase 2 trial","volume":"115","author":"Adkins","year":"2021","journal-title":"Oral. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118871_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103476","article-title":"A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody","volume":"9","author":"Koyama","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.biopha.2025.118871_bib139","unstructured":"Washington University School of Medicine. Phase II Trial of Nab-Paclitaxel, Cisplatin, and 5-FU (ACF) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) [Internet]. clinicaltrials.gov; 2020 Sept [cited 2025 Mar 22]. Report No., NCT01566435. Available from, \u3008https:\/\/clinicaltrials.gov\/study\/NCT01566435\u3009."},{"key":"10.1016\/j.biopha.2025.118871_bib140","unstructured":"University of Chicago. A Phase II Trial of Nivolumab\/Nab-paclitaxel\/Carboplatin Induction Chemotherapy Followed by Response-stratified Locoregional Therapy for Patients With Locoregionally Advanced HPV-related Oropharyngeal Cancer- the OPTIMA II Trial [Internet]. clinicaltrials.gov; 2024 Oct [cited 2025 Mar 25]. Report No., NCT03107182. Available from, \u3008https:\/\/clinicaltrials.gov\/study\/NCT03107182\u3009."},{"key":"10.1016\/j.biopha.2025.118871_bib141","unstructured":"ModernaTX, Inc. A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36\u03b3, for Intratumoral Injection Alone and in Combination With Immune Checkpoint Blockade [Internet]. clinicaltrials.gov; 2024 May [cited 2025 Mar 22]. Report No., NCT03739931. Available from, \u3008https:\/\/clinicaltrials.gov\/study\/NCT03739931\u3009."},{"key":"10.1016\/j.biopha.2025.118871_bib142","unstructured":"Johnson & Johnson Enterprise Innovation Inc. A Phase 3 Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC [Internet]. clinicaltrials.gov; 2025 Mar [cited 2025 Mar 25]. Report No., NCT04892173. Available from, \u3008https:\/\/clinicaltrials.gov\/study\/NCT04892173\u3009."},{"key":"10.1016\/j.biopha.2025.118871_bib143","unstructured":"M.D. Anderson Cancer Center. Phase II Study of NBTXR3 Activated by Radiation and Combined With Pembrolizumab for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With Limited PD-L1 Expression or Refractory to PD-1 Blockade [Internet]. clinicaltrials.gov; 2024 Apr [cited 2025 Mar 22]. Report No., NCT04862455. Available from, \u3008https:\/\/clinicaltrials.gov\/study\/NCT04862455\u3009."},{"key":"10.1016\/j.biopha.2025.118871_bib144","unstructured":"M.D. Anderson Cancer Center. A Phase II Study of Reirradiation With NBTXR3 in Patients With Inoperable Locoregional Recurrent Head and Neck Squamous Cell Carcinoma [Internet]. clinicaltrials.gov; 2023 Sept [cited 2025 Mar 22]. Report No., NCT04834349. Available from, \u3008https:\/\/clinicaltrials.gov\/study\/NCT04834349\u3009."},{"key":"10.1016\/j.biopha.2025.118871_bib145","unstructured":"M.D. Anderson Cancer Center. Pilot Feasibility Study of Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI for Primary and Nodal Tumor Imaging in Locally Advanced Head and Neck Squamous Cell Carcinomas [Internet]. clinicaltrials.gov; 2021 Sept [cited 2025 Mar 25]. Report No., NCT01895829. Available from, \u3008https:\/\/clinicaltrials.gov\/study\/NCT01895829\u3009."},{"key":"10.1016\/j.biopha.2025.118871_bib146","unstructured":"University of Southern California. A Pilot Multi-arm Study of sEphB4-HSA in Combination With Different Chemotherapy Regimens in Patients With Specific Advanced or Metastatic Solid Tumors [Internet]. clinicaltrials.gov; 2023 Aug [cited 2025 Mar 22]. Report No., NCT02495896. Available from, \u3008https:\/\/clinicaltrials.gov\/study\/NCT02495896\u3009."},{"key":"10.1016\/j.biopha.2025.118871_bib147","unstructured":"University of Chicago. Nab-Paclitaxel-based Re-induction Chemotherapy Followed by Response-stratified Chemoradiotherapy in Patients With Previously Treated Squamous Cell Carcinoma of the Head and Neck. [Internet]. clinicaltrials.gov; 2024 July [cited 2025 Mar 22]. Report No., NCT01847326. Available from, \u3008https:\/\/clinicaltrials.gov\/study\/NCT01847326\u3009."},{"key":"10.1016\/j.biopha.2025.118871_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114778","article-title":"New advances into cisplatin resistance in head and neck squamous carcinoma, Mechanisms and therapeutic aspects","volume":"163","author":"Hu","year":"2023","journal-title":"Biomed. Pharm."},{"issue":"5","key":"10.1016\/j.biopha.2025.118871_bib149","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/wnan.1390","article-title":"Nanoparticle formulations of cisplatin for cancer therapy","volume":"8","author":"Duan","year":"2016","journal-title":"WIREs Nanomed. Nanobiotechnology"},{"issue":"13","key":"10.1016\/j.biopha.2025.118871_bib150","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.2017.72.7107","article-title":"Phosphatidylinositol 3-Kinase \u03b1\u2013Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors, Results From the First-in-Human Study","volume":"36","author":"Juric","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib151","first-page":"1","article-title":"Targeted therapy for head and neck cancer, signaling pathways and clinical studies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"issue":"52","key":"10.1016\/j.biopha.2025.118871_bib152","doi-asserted-by":"crossref","first-page":"38668","DOI":"10.1039\/D4RA07193J","article-title":"Advances in nanotechnology-based approaches for the treatment of head and neck squamous cell carcinoma","volume":"14","author":"Tang","year":"2024","journal-title":"RSC Adv."},{"issue":"28","key":"10.1016\/j.biopha.2025.118871_bib153","article-title":"Nonpersistent Nanoarchitectures Enhance Concurrent Chemoradiotherapy in an Immunocompetent Orthotopic Model of HPV+ Head\/Neck Carcinoma","volume":"36","author":"Gonnelli","year":"2024","journal-title":"Adv. Mater."},{"issue":"39","key":"10.1016\/j.biopha.2025.118871_bib154","doi-asserted-by":"crossref","first-page":"33060","DOI":"10.1021\/acsami.8b12926","article-title":"Microneedle-mediated delivery of lipid-coated cisplatin nanoparticles for efficient and safe cancer therapy","volume":"10","author":"Lan","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.biopha.2025.118871_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2019.110566","article-title":"Synthesis of novel N-vinylpyrrolidone\/acrylic acid nanoparticles as drug delivery carriers of cisplatin to cancer cells","volume":"185","author":"Pornpitchanarong","year":"2020","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"2","key":"10.1016\/j.biopha.2025.118871_bib156","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1021\/nn800551s","article-title":"Targeted Killing of Cancer Cells in Vivo and in Vitro with EGF-Directed Carbon Nanotube-Based Drug Delivery","volume":"3","author":"Bhirde","year":"2009","journal-title":"ACS Nano"},{"issue":"12","key":"10.1016\/j.biopha.2025.118871_bib157","first-page":"3534","article-title":"Safety and efficacy of quadrapeutics versus chemoradiation in head and neck carcinoma xenograft model","volume":"5","author":"Lukianova-Hleb","year":"2015","journal-title":"Am. J. Cancer Res"},{"key":"10.1016\/j.biopha.2025.118871_bib158","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.2147\/IJN.S46327","article-title":"Expression of folate receptors in nasopharyngeal and laryngeal carcinoma and folate receptor-mediated endocytosis by molecular targeted nanomedicine","volume":"8","author":"Xie","year":"2013","journal-title":"Int J. Nanomed."},{"issue":"4","key":"10.1016\/j.biopha.2025.118871_bib159","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/hed.21003","article-title":"Examining expression of folate receptor in squamous cell carcinoma of the head and neck as a target for a novel nanotherapeutic drug","volume":"31","author":"Saba","year":"2009","journal-title":"Head. Neck"},{"key":"10.1016\/j.biopha.2025.118871_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.138976","article-title":"Folate receptor-targeted thiol-maleimide clicked chitosan\/carboxymethyl cellulose nanoparticles for cisplatin delivery in oral carcinoma","volume":"290","author":"Patrojanasophon","year":"2025","journal-title":"Int J. Biol. Macromol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118871_bib161","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.3390\/biom11121850","article-title":"CD44, A Multifunctional Mediator of Cancer Progression","volume":"11","author":"Hassn Mesrati","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2025.118871_bib162","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1257898","article-title":"Targeted therapy for head and neck squamous cell carcinoma microenvironment","volume":"10","author":"Guo","year":"2023","journal-title":"Front Med"},{"issue":"6","key":"10.1016\/j.biopha.2025.118871_bib163","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/j.xphs.2016.03.018","article-title":"Hyaluronan-Lysine Cisplatin Drug Carrier for Treatment of Localized Cancers, Pharmacokinetics, Tolerability, and Efficacy in Rodents and Canines","volume":"105","author":"Zhang","year":"2016","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib164","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/hed.24935","article-title":"Cisplatin-conjugated gold nanoparticles as a theranostic agent for head and neck cancer","volume":"40","author":"Davidi","year":"2018","journal-title":"Head. Neck"},{"issue":"12","key":"10.1016\/j.biopha.2025.118871_bib165","first-page":"4939","article-title":"Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model","volume":"6","author":"Harrington","year":"2000","journal-title":"Clin. Cancer Res"},{"issue":"11","key":"10.1016\/j.biopha.2025.118871_bib166","doi-asserted-by":"crossref","first-page":"18541","DOI":"10.1021\/acsnano.1c08632","article-title":"Targeting Cancer Chemotherapy Resistance by Precision Medicine-Driven Nanoparticle-Formulated Cisplatin","volume":"15","author":"Siemer","year":"2021","journal-title":"ACS Nano"},{"issue":"9","key":"10.1016\/j.biopha.2025.118871_bib167","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3390\/cancers10090311","article-title":"Insonation of Systemically Delivered Cisplatin-Loaded Microbubbles Significantly Attenuates Nephrotoxicity of Chemotherapy in Experimental Models of Head and Neck Cancer","volume":"10","author":"Chen","year":"2018","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.biopha.2025.118871_bib168","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2217\/nnm.09.56","article-title":"Imaging The Distribution of Individual Platinum-Based Anticancer Drug Molecules Attached to Single-Wall Carbon Nanotubes","volume":"4","author":"Bhirde","year":"2009","journal-title":"Nanomed"},{"key":"10.1016\/j.biopha.2025.118871_bib169","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jconrel.2017.06.021","article-title":"cRGD peptide installation on cisplatin-loaded nanomedicines enhances efficacy against locally advanced head and neck squamous cell carcinoma bearing cancer stem-like cells","volume":"261","author":"Miyano","year":"2017","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.biopha.2025.118871_bib170","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3109\/1061186X.2014.921924","article-title":"Cellular uptake and internalization of hyaluronan-based doxorubicin and cisplatin conjugates","volume":"22","author":"Cai","year":"2014","journal-title":"J. Drug Target"},{"key":"10.1016\/j.biopha.2025.118871_bib171","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14292","article-title":"Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma","volume":"8","author":"Mizrachi","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib172","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2024.2449376","article-title":"In vivo antitumor activity of PHT-427 inhibitor-loaded polymeric nanoparticles in head and neck squamous cell carcinoma","volume":"32","author":"Yanes-D\u00edaz","year":"2025","journal-title":"Drug Deliv."},{"issue":"2","key":"10.1016\/j.biopha.2025.118871_bib173","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jconrel.2012.11.007","article-title":"Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells","volume":"165","author":"Altintas","year":"2013","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib174","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-018-0623-3","article-title":"Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib","volume":"11","author":"Lang","year":"2018","journal-title":"J. Hematol. OncolJ Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118871_bib175","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1021\/acsptsci.2c00033","article-title":"Craft of Co-encapsulation in Nanomedicine, A Struggle To Achieve Synergy through Reciprocity","volume":"5","author":"Bhattacharjee","year":"2022","journal-title":"ACS Pharm. Transl. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2025.118871_bib176","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.3390\/molecules28031449","article-title":"Co-Encapsulation of Drugs for Topical Application\u2014A Review","volume":"28","author":"Ataide","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2025.118871_bib177","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.994655","article-title":"Nanocarriers for intracellular co-delivery of proteins and small-molecule drugs for cancer therapy","author":"Cheng","year":"2022","journal-title":"Front Bioeng. Biotechnol. [Internet]"},{"key":"10.1016\/j.biopha.2025.118871_bib178","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2024.04.020","article-title":"Nanodrugs based on co-delivery strategies to combat cisplatin resistance","volume":"370","author":"Wang","year":"2024","journal-title":"J. Control. Release"},{"issue":"36","key":"10.1016\/j.biopha.2025.118871_bib179","doi-asserted-by":"crossref","first-page":"18885","DOI":"10.1039\/D0NR04213G","article-title":"Microneedles loaded with anti-PD-1\u2013cisplatin nanoparticles for synergistic cancer immuno-chemotherapy","volume":"12","author":"Lan","year":"2020","journal-title":"Nanoscale"},{"issue":"6","key":"10.1016\/j.biopha.2025.118871_bib180","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1016\/j.apsb.2024.02.009","article-title":"Cisplatin-based miRNA delivery strategy inspired by the circCPNE1\/miR-330-3p pathway for oral squamous cell carcinoma","volume":"14","author":"Fan","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib181","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-019-0827-1","article-title":"Simultaneously inactivating Src and AKT by saracatinib\/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma","volume":"12","author":"Lang","year":"2019","journal-title":"J. Hematol. OncolJ Hematol. Oncol."},{"key":"10.1016\/j.biopha.2025.118871_bib182","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.2147\/OTT.S286813","article-title":"Lipid\u2013Polymer Hybrid Nanoparticle-Based Combination Treatment with Cisplatin and EGFR\/HER2 Receptor-Targeting Afatinib to Enhance the Treatment of Nasopharyngeal Carcinoma","volume":"14","author":"Fu","year":"2021","journal-title":"OncoTargets Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib183","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1080\/10717544.2016.1236849","article-title":"Cisplatin and paclitaxel co-delivered by folate-decorated lipid carriers for the treatment of head and neck cancer","volume":"24","author":"Yang","year":"2017","journal-title":"Drug Deliv."},{"key":"10.1016\/j.biopha.2025.118871_bib184","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4028\/www.scientific.net\/KEM.901.123","article-title":"Effect of Cisplatin\/Curcumin-Loaded Polycaprolactone Nanoparticles on Oral Carcinoma Cells","volume":"901","author":"Pornpitchanarong","year":"2021","journal-title":"Key Eng. Mater."},{"issue":"1","key":"10.1016\/j.biopha.2025.118871_bib185","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1186\/s12951-021-01125-7","article-title":"Gelatinase-sensitive nanoparticles loaded with photosensitizer and STAT3 inhibitor for cancer photothermal therapy and immunotherapy","volume":"19","author":"Bu","year":"2021","journal-title":"J. Nanobiotechnology"},{"issue":"12","key":"10.1016\/j.biopha.2025.118871_bib186","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1039\/C9BM01192G","article-title":"A near infrared light-triggered human serum albumin drug delivery system with coordination bonding of indocyanine green and cisplatin for targeting photochemistry therapy against oral squamous cell cancer","volume":"7","author":"Wang","year":"2019","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.biopha.2025.118871_bib187","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jconrel.2022.01.040","article-title":"Loco-regional radiosensitizing nanoparticles-in-gel augments head and neck cancer chemoradiotherapy","volume":"343","author":"Bhardwaj","year":"2022","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.biopha.2025.118871_bib188","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1039\/D2TB01930B","article-title":"Hybrid nano-architectures loaded with metal complexes for the co-chemotherapy of head and neck carcinomas","volume":"11","author":"Santi","year":"2023","journal-title":"J. Mater. Chem. B"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225010650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225010650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:30:37Z","timestamp":1778754637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225010650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":188,"alternative-id":["S0753332225010650"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118871","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanotechnology-based approaches for head and neck cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118871","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118871"}}